Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05744076
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-02-24
First Post:
2023-02-14
Brief Title:
Analysis of Circulating Exosomes in Melanoma Patients
Sponsor:
Centre Hospitalier Universitaire de Besancon
Organization:
Centre Hospitalier Universitaire de Besancon
Study Overview
Official Title:
Analysis of Circulating Exosomes in Melanoma Patients
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EXOMEL1
Brief Summary:
The hypothesis is that PD-L1Programmed Death-Ligand 1 labeling in exosomes could be a biomarker of disease progression in melanoma The rate of circulating exosomes their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease the response to treatment andor the prognosis of patients In this study blood samples EDTA tubes taken as part of routine care at Besançon University Hospital and associated clinical data are reused
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None